公开(公告)号：US20190216882A1

公开(公告)日：2019-07-18

申请号：US16227994

申请日：2018-12-20

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K38/06 ,  A61K31/4184 ,  A61K31/498 ,  A61K31/454 ,  A61K9/24 ,  A61K9/16 ,  A61K9/20 ,  A61K9/14 ,  A61K9/28

CPC classification number: A61K38/06 ,  A61K9/146 ,  A61K9/1688 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2866 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K2300/00

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US20200253968A1

公开(公告)日：2020-08-13

申请号：US16654442

申请日：2019-10-16

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K31/498 ,  A61K31/454 ,  A61K9/24 ,  A61K9/20 ,  A61K9/14 ,  A61K31/4985

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US11246866B2

公开(公告)日：2022-02-15

申请号：US16654442

申请日：2019-10-16

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K31/498 ,  A61K9/28 ,  A61K9/20 ,  A61K31/454 ,  A61K9/24 ,  A61K9/14 ,  A61K31/4985

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US20200282004A1

公开(公告)日：2020-09-10

申请号：US16654433

申请日：2019-10-16

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K38/06 ,  A61K9/14 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K31/498 ,  A61K9/16 ,  A61K9/28 ,  A61K31/4184

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US20240075026A1

公开(公告)日：2024-03-07

申请号：US18107243

申请日：2023-02-08

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K31/498 ,  A61K9/14 ,  A61K9/20 ,  A61K9/24 ,  A61K31/454 ,  A61K31/4985

CPC classification number: A61K31/498 ,  A61K9/146 ,  A61K9/2027 ,  A61K9/209 ,  A61K31/454 ,  A61K31/4985

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.

公开(公告)号：US20160375087A1

公开(公告)日：2016-12-29

申请号：US15192211

申请日：2016-06-24

Applicant: AbbVie Inc.

Inventor： Nancy E. Sever ,  Ulrich Westedt ,  Ute Lander ,  Katrin Schneider ,  Benedikt Steitz ,  Thomas Mueller ,  Regina Reul ,  Constanze Obermiller ,  Adivaraha Jayasankar ,  Michael Simon ,  Yi Gao ,  Harald Hach ,  Samuel Kyeremateng ,  Katharina Asmus ,  Ping Tong ,  Donghua Zhu ,  Marius Naris ,  Colleen Garrett

IPC: A61K38/06 ,  A61K9/28 ,  A61K9/20 ,  A61K9/16 ,  A61K31/4184 ,  A61K9/24

CPC classification number: A61K38/06 ,  A61K9/146 ,  A61K9/1688 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2866 ,  A61K31/4184 ,  A61K31/454 ,  A61K31/498 ,  A61K2300/00

Abstract: The present invention features solid pharmaceutical compositions comprising Compound 1 and Compound 2. In one embodiment, the solid pharmaceutical composition includes (1) a first layer which comprises 100 mg Compound 1, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion; and (2) a second layer which comprises 40 mg Compound 2, as well as a pharmaceutically acceptable hydrophilic polymer and a pharmaceutically acceptable surfactant, all of which are formulated in amorphous solid dispersion.